Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.48 |
| ▸ | SMG1 | Q96Q15 | 3/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16025720 | 0.89 | LRRK2 (0.48) | LRRK2SMG1MAPTMTOR | |
| SCHEMBL17430360 | 0.86 | LRRK2 (0.46) | LRRK2SMG1MTOR | |
| SCHEMBL17430366 | 0.86 | LRRK2 (0.46) | LRRK2SMG1MTORRAF1BRAF | |
| SCHEMBL16025886 | 0.86 | LRRK2 (0.61) | LRRK2SMG1CYP2C9 | |
| SCHEMBL16025891 | 0.85 | LRRK2 (0.47) | LRRK2SMG1MEN1KMT2A | |
| SCHEMBL16025865 | 0.84 | PIK3CA (0.43) | LRRK2SMG1KMT2ARAF1BRAF | |
| SCHEMBL16023497 | 0.84 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL16525450 | 0.84 | LRRK2 (0.48) | LRRK2SMG1CDK1CDK2MTOR | |
| SCHEMBL16025889 | 0.83 | LRRK2 (0.51) | LRRK2SMG1CYP2C9 | |
| SCHEMBL16025988 | 0.83 | LRRK2 (0.50) | LRRK2SMG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | LRRK2 1/4885SMG1 699/4885CDK1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.